Search

Displaying results 1621 - 1630 of 8410 in total
  1. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … [A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    AZD-8418

    go.drugbank.com/drugs/DB13102
    Investigational

    Azd8418 is under investigation in clinical trial NCT01027234 (This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses).

  3. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  4. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia.

  5. Drug

    Leflunomide

    go.drugbank.com/drugs/DB01097
    ApprovedInvestigational

    Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many othe...

    Synonyms: alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  6. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one

  7. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  8. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to

    Categories: P-glycoprotein inducers, Cytochrome P-450 Substrates
  9. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. Mo...

  10. Drug

    Potassium

    go.drugbank.com/drugs/DB14500
    ApprovedInvestigational

    They are available in an assortment of tablet, injection, and other forms, depending on the setting and condition being treated. … Potassium is an essential nutrient, like [Calcium] and [Magnesium]. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans.

    Mixtures: Cal & Mag Hvp Chel Plus C Potass & Zinc Tab, Liquid Opti-minplex +d